Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
PEN's Cash-to-Debt is ranked higher than
74% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. PEN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.28  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.87
PEN's Equity-to-Asset is ranked higher than
91% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. PEN: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
PEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.11  Med: 0.38 Max: 0.88
Current: 0.87
-0.11
0.88
Interest Coverage No Debt
PEN's Interest Coverage is ranked higher than
77% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. PEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PEN' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 1
Altman Z-Score: 37.59
Beneish M-Score: -1.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -0.51
PEN's Operating Margin % is ranked lower than
56% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. PEN: -0.51 )
Ranked among companies with meaningful Operating Margin % only.
PEN' s Operating Margin % Range Over the Past 10 Years
Min: -1.27  Med: 0.87 Max: 2.4
Current: -0.51
-1.27
2.4
Net Margin % -0.96
PEN's Net Margin % is ranked lower than
56% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. PEN: -0.96 )
Ranked among companies with meaningful Net Margin % only.
PEN' s Net Margin % Range Over the Past 10 Years
Min: -0.96  Med: 3.2 Max: 5.63
Current: -0.96
-0.96
5.63
ROE % -1.02
PEN's ROE % is ranked lower than
57% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. PEN: -1.02 )
Ranked among companies with meaningful ROE % only.
PEN' s ROE % Range Over the Past 10 Years
Min: -1.02  Med: 3.46 Max: 5.94
Current: -1.02
-1.02
5.94
ROA % -0.89
PEN's ROA % is ranked lower than
53% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. PEN: -0.89 )
Ranked among companies with meaningful ROA % only.
PEN' s ROA % Range Over the Past 10 Years
Min: -0.89  Med: 3.76 Max: 5.76
Current: -0.89
-0.89
5.76
ROC (Joel Greenblatt) % -1.39
PEN's ROC (Joel Greenblatt) % is ranked lower than
53% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. PEN: -1.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3.24  Med: 2.67 Max: 7.26
Current: -1.39
-3.24
7.26
GuruFocus has detected 6 Warning Signs with Penumbra Inc $PEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PEN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PEN Guru Trades in Q1 2016

Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 86,800 sh (-14.31%)
» More
Q2 2016

PEN Guru Trades in Q2 2016

Paul Tudor Jones 5,500 sh (New)
Jim Simons 158,600 sh (New)
Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 84,600 sh (-2.53%)
» More
Q3 2016

PEN Guru Trades in Q3 2016

Steven Cohen 24,700 sh (New)
Pioneer Investments 58,492 sh (New)
Jim Simons 186,500 sh (+17.59%)
Chuck Royce 1,000 sh (unchged)
Paul Tudor Jones Sold Out
PRIMECAP Management 79,100 sh (-6.50%)
» More
Q4 2016

PEN Guru Trades in Q4 2016

Pioneer Investments 67,629 sh (+15.62%)
Chuck Royce 1,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
PRIMECAP Management 66,000 sh (-16.56%)
» More
» Details

Insider Trades

Latest Guru Trades with PEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339999    SIC: 3841
Compare: » details
Traded in other countries:0P8.Germany,
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Penumbra Inc was incorporated in 2004 as a Delaware corporation under the name Penumbra. It is an interventional therapies company that designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company sells its products to hospitals through its salesforce, as well as through distributors. It sells its products through direct sales organization in the United States, Europe, Canada and Australia. Its products include Penumbra System, ACE, Penumbra Coil 400, Penumbra SMART COIL, LIBERTY Stent, Apollo System, Ruby Coil and Indigo System. The Company competes with manufacturers and distributors of neurovascular and peripheral vascular medical devices. Its competitors are Boston Scientific, Johnson & Johnson, Medtronic, Stryker and Terumo. Its products are medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act), and its implementing regulations, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries under other statutes and regulations.

Ratios

vs
industry
vs
history
PB Ratio 9.58
PEN's PB Ratio is ranked lower than
88% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. PEN: 9.58 )
Ranked among companies with meaningful PB Ratio only.
PEN' s PB Ratio Range Over the Past 10 Years
Min: 4.83  Med: 7.33 Max: 9.87
Current: 9.58
4.83
9.87
PS Ratio 9.85
PEN's PS Ratio is ranked lower than
82% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. PEN: 9.85 )
Ranked among companies with meaningful PS Ratio only.
PEN' s PS Ratio Range Over the Past 10 Years
Min: 3.57  Med: 4.8 Max: 10.17
Current: 9.85
3.57
10.17
EV-to-EBITDA 5433.80
PEN's EV-to-EBITDA is ranked lower than
100% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. PEN: 5433.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
PEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 52.7  Med: 336.55 Max: 5604.03
Current: 5433.8
52.7
5604.03
Current Ratio 7.37
PEN's Current Ratio is ranked higher than
92% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. PEN: 7.37 )
Ranked among companies with meaningful Current Ratio only.
PEN' s Current Ratio Range Over the Past 10 Years
Min: 3.93  Med: 6.46 Max: 8.68
Current: 7.37
3.93
8.68
Quick Ratio 5.33
PEN's Quick Ratio is ranked higher than
90% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. PEN: 5.33 )
Ranked among companies with meaningful Quick Ratio only.
PEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.22  Med: 4.63 Max: 6.66
Current: 5.33
2.22
6.66
Days Inventory 264.28
PEN's Days Inventory is ranked lower than
81% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. PEN: 264.28 )
Ranked among companies with meaningful Days Inventory only.
PEN' s Days Inventory Range Over the Past 10 Years
Min: 256.07  Med: 262.12 Max: 318.98
Current: 264.28
256.07
318.98
Days Sales Outstanding 60.07
PEN's Days Sales Outstanding is ranked higher than
60% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. PEN: 60.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
PEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.71  Med: 56.38 Max: 60.07
Current: 60.07
53.71
60.07
Days Payable 16.22
PEN's Days Payable is ranked lower than
90% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. PEN: 16.22 )
Ranked among companies with meaningful Days Payable only.
PEN' s Days Payable Range Over the Past 10 Years
Min: 15.1  Med: 15.84 Max: 20.09
Current: 16.22
15.1
20.09

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 29.09
PEN's Price-to-Net-Cash is ranked lower than
70% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.38 vs. PEN: 29.09 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 13.69  Med: 18.24 Max: 30.02
Current: 29.09
13.69
30.02
Price-to-Net-Current-Asset-Value 11.41
PEN's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. PEN: 11.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.56  Med: 8.25 Max: 11.77
Current: 11.41
7.56
11.77
Price-to-Tangible-Book 9.50
PEN's Price-to-Tangible-Book is ranked lower than
79% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. PEN: 9.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.92  Med: 7.19 Max: 9.81
Current: 9.5
6.92
9.81
Price-to-Median-PS-Value 2.04
PEN's Price-to-Median-PS-Value is ranked lower than
86% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. PEN: 2.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.28 Max: 2.1
Current: 2.04
0.96
2.1
Earnings Yield (Greenblatt) % -0.06
PEN's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. PEN: -0.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.06  Med: 0.3 Max: 1.2
Current: -0.06
-0.06
1.2

More Statistics

Revenue (TTM) (Mil) $263.3
EPS (TTM) $ -0.09
Short Percentage of Float12.26%
52-Week Range $43.68 - 84.80
Shares Outstanding (Mil)33.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 316 374 436
EPS ($) -0.02 0.34 0.74
EPS without NRI ($) -0.02 0.34 0.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
PENUMBRA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Mar 22 2017
Owens & Minor (OMI) Reaffirms Tepid 2017 Financial Guidance Mar 17 2017
Penumbra, Inc. Announces Pricing of Offering of 1,300,000 Shares of its Common Stock Mar 16 2017
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4 Mar 16 2017
Penumbra, Inc. Announces Launch of Offering of 1,300,000 Shares of its Common Stock Mar 15 2017
Cogentix (CGNT) Q4 Earnings and Revenues Miss Estimates Mar 10 2017
There Is a $10 Million Job Now Up for Grabs -- Think You Can Get It? Mar 09 2017
PENUMBRA INC Financials Mar 04 2017
Penumbra, Inc. :PEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
Penumbra Announces Key Events at Society of Interventional Radiology 2017 Meeting Mar 02 2017
Penumbra (PEN) Q4 Loss Narrower than Expected, Sales Top Mar 01 2017
Edited Transcript of PEN earnings conference call or presentation 28-Feb-17 10:00pm GMT Mar 01 2017
Penumbra reports 4Q loss Feb 28 2017
Penumbra reports 4Q loss Feb 28 2017
PENUMBRA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 28 2017
Penumbra, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results Feb 28 2017
Q4 2016 Penumbra Inc Earnings Release - After Market Close Feb 28 2017
Independent Study Supports Use of Penumbra Aspiration as Frontline Thrombectomy Therapy for Acute... Feb 22 2017
Can Penumbra (PEN) Spring a Surprise this Earnings Season? Feb 22 2017
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for... Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)